The purpose of the Boston University Alzheimer's Disease Center (BU ADC) is to promote research on Alzheimer's Disease (AD) at BU and throughout the country by providing information and materials from well characterized patient, control and caregiver populations drawn from the ambulatory and late-stage suburban population at the Bedord VA Medical Center and the racially, ethnically, and culturally diverse poor urban Registry of the Clinical Core are assessed annually with a standardized neurological examination and neuropsychological test battery. Blood is obtained and stored for molecular genetic studies. A detailed family neuropsychological test battery. Blood is obtained and stored for molecular genetic studies. A detailed family history is obtained and a separate Caregiver Registry collects annual standardized information on family and professional caregivers. This information is entered into a database for longitudinal comparisons and correlation with the progression of AD and its impact on caregivers. Subjects, data and blood/DNA are made available to qualified researchers to stimulate new research in AD and normal aging. The Neuropathology Core establishes accurate pathological diagnoses, rigorous documentation and quantitation of neuropathological changes, harvests endothelial cells, and collects, stores and disburses post-mortem tissue. The Education and Information Transfer Core supports the development of physicians and other professional caregivers to improve clinical and research skills related to AD and provide outreach programs to increase caregivers' and the lay public's knowledge of AD. Nationally, this Core collaborates with other ADCs, ADEAR Center, Alzheimer Association and other groups to advance AD care, education, and research. The Murine Breeding and Molecular Genetics Core maintains a transgenic mouse colony as well as several colonies of mice with AD-related phenotypes including: 1) increased or decreased susceptibility to oxidative injury 2) Calreticulin Knockout mice 3) over expression or under expression of APOE. This comprehensive breeding facility is a unique resource for investigators. The BU ADC funds pilot projects to promote new AD research and fosters the development of new AD investigators. These multiple activities are coordinated by the Administrative Core. The BU ADC has greatly strengthened and expanded AD research at BU and has facilitated the involvement of African Americans in aging and dementia research. The BU ADC has promoted and supported AD research on a comprehensive range of topics including pathogenesis, animal models, neuropathology, genetic and environmental risk and protective factors, late-stage dementia, and the impact of disease burden on caregivers and society.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG013846-09
Application #
6767606
Study Section
Special Emphasis Panel (ZAG1-PCR-5 (M1))
Program Officer
Phelps, Creighton H
Project Start
1996-07-01
Project End
2006-06-30
Budget Start
2004-07-15
Budget End
2005-06-30
Support Year
9
Fiscal Year
2004
Total Cost
$1,186,683
Indirect Cost
Name
Boston University
Department
Neurology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Cherry, Jonathan D; Mez, Jesse; Crary, John F et al. (2018) Variation in TMEM106B in chronic traumatic encephalopathy. Acta Neuropathol Commun 6:115
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Li, Dan; Wang, Lei; Maziuk, Brandon F et al. (2018) Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau. J Biol Chem 293:12081-12094
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Tagge, Chad A; Fisher, Andrew M; Minaeva, Olga V et al. (2018) Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model. Brain 141:422-458
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325

Showing the most recent 10 out of 791 publications